The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
Open Access
- 30 June 2021
- Vol. 2 (3), 392-402
- https://doi.org/10.3390/hemato2030025
Abstract
Patients with myeloproliferative neoplasm (MPN) are potentially facing diminished life expectancy and decreased quality of life, due to thromboembolic and hemorrhagic complications, progression to myelofibrosis or acute leukemia with ensuing signs of hematopoietic insufficiency, and disturbing symptoms such as pruritus, night sweats, and bone pain. In patients with essential thrombocythemia (ET) or polycythemia vera (PV), current guidelines recommend both primary and secondary measures to prevent thrombosis. These include acetylsalicylic acid (ASA) for patients with intermediate- or high-risk ET and all patients with PV, unless they have contraindications for ASA use, and phlebotomy for all PV patients. A target hematocrit level below 45% is demonstrated to be associated with decreased cardiovascular events in PV. In addition, cytoreductive therapy is shown to reduce the rate of thrombotic complications in high-risk ET and high-risk PV patients. In patients with prefibrotic primary myelofibrosis (pre-PMF), similar measures are recommended as in those with ET. Patients with overt PMF may be at increased risk of bleeding and thus require a more individualized approach to thrombosis prevention. This review summarizes the thrombotic risk factors and primary and secondary preventive measures against thrombosis in MPN.Keywords
This publication has 68 references indexed in Scilit:
- Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐upEuropean Journal of Haematology, 2019
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussionBlood Cancer Journal, 2018
- Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative NeoplasmsAnnals of Internal Medicine, 2018
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based StudyJournal of Clinical Oncology, 2015
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based StudyJournal of Clinical Oncology, 2012
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patientsBlood, 2011
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsHaematologica, 2008
- Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patientsLeukemia, 1999
- Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.Journal of Clinical Oncology, 1990